Suppr超能文献

利用大型前瞻性临床试验数据库(ACOSOG Z0030)验证肺癌分期系统修订版。

Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030).

机构信息

Division of General Thoracic Surgery, Mayo Clinic, Rochester, MN, USA.

出版信息

Eur J Cardiothorac Surg. 2013 May;43(5):911-4. doi: 10.1093/ejcts/ezs520. Epub 2012 Sep 26.

Abstract

OBJECTIVES

A new revision of the international lung cancer staging system has been recently introduced. The revisions are largely focussed on the T descriptor. We sought to test the validity of this new system on a separate prospectively collected cohort of patients from a recent multicentre trial of early-stage lung cancer.

METHODS

We reviewed the prospectively collected data from 1012 patients undergoing pulmonary resection for early-stage lung cancer in the ACOSOG Z0030 trial. TNM descriptors and overall staging were assessed using both the sixth and seventh editions of the American Joint Committee on Cancer and the Union Internationale Contre le Cancer (AJCC/UICC) lung cancer staging system. Survival results were analysed according to both staging allocations.

RESULTS

Using the proposed criteria, the number of patients by stage in the sixth and seventh edition allocations, respectively, were as follows: IA (432, 431); IB (402, 303); IIA (39, 167); IIB (94, 70); IIIA (26, 40); IIIB (19,0); there were no stage IV patients by either version. Overall, 180 (18%) patients had a change in the stage group from the sixth to seventh edition versions with 76 (8%) being downstaged and 104 (10%) being upstaged. In the sixth edition staging system based on pathological stages, median survivals in years were as follows: IA, NA; IB, 7.7; IIA, 4.0; IIB, 3.6; IIIA, 2.6 and IIIB, 2.4. Five-year survivals were: IA, 76.4%; IB, 62.0%; IIA, 47.8%; IIB, 40.4%; IIIA, 31.3% and IIIB, 44.4%. In the new system, median survivals in years were as follows: IA, NA; IB, 8.2; IIA, 4.4; IIB, 3.6 and IIIA, 1.8. Five-year survivals were: IA, 76.9%; IB, 65.0%; IIA, 48.5%; IIB, 42.9% and IIIA, 30.6%. Survival analysis and Kaplan-Meier survival curves showed more monotonic progression, distinction and homogeneity within groups in the seventh edition.

CONCLUSIONS

This study provides an external validation of the recently revised lung cancer staging system using a large multicentre database. The seventh edition of the AJCC/UICC lung cancer staging system appears to be an improvement over the preceding system.

摘要

目的

最近引入了国际肺癌分期系统的新版本修订。修订主要集中在 T 描述符上。我们试图在最近的一项早期肺癌多中心试验的另一个前瞻性收集队列中测试这个新系统的有效性。

方法

我们回顾了 ACOSOG Z0030 试验中 1012 例接受肺切除术治疗的早期肺癌患者的前瞻性收集数据。使用第六和第七版美国癌症联合委员会/国际抗癌联盟(AJCC/UICC)肺癌分期系统评估 TNM 描述符和总体分期。根据两种分期分配方法分析生存结果。

结果

使用提出的标准,第六版和第七版分配的各期患者数量如下:IA(432,431);IB(402,303);IIA(39,167);IIB(94,70);IIIA(26,40);IIIB(19,0);两种版本均无 IV 期患者。总体而言,180 例(18%)患者的分期组从第六版到第七版发生变化,76 例(8%)降期,104 例(10%)升期。在基于病理分期的第六版分期系统中,中位生存年限如下:IA,NA;IB,7.7;IIA,4.0;IIB,3.6;IIIA,2.6 和 IIIB,2.4。5 年生存率分别为:IA,76.4%;IB,62.0%;IIA,47.8%;IIB,40.4%;IIIA,31.3%和 IIIB,44.4%。在新系统中,中位生存年限如下:IA,NA;IB,8.2;IIA,4.4;IIB,3.6 和 IIIA,1.8。5 年生存率分别为:IA,76.9%;IB,65.0%;IIA,48.5%;IIB,42.9%和 IIIA,30.6%。生存分析和 Kaplan-Meier 生存曲线显示,第七版在组内具有更单调的进展、区分和同质性。

结论

本研究使用大型多中心数据库为最近修订的肺癌分期系统提供了外部验证。第七版 AJCC/UICC 肺癌分期系统似乎优于前一版。

相似文献

1
Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030).
Eur J Cardiothorac Surg. 2013 May;43(5):911-4. doi: 10.1093/ejcts/ezs520. Epub 2012 Sep 26.
3
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution.
J Thorac Cardiovasc Surg. 2009 May;137(5):1180-4. doi: 10.1016/j.jtcvs.2008.09.030. Epub 2009 Mar 9.
4
Validation of the Eighth Edition TNM Lung Cancer Staging System.
J Thorac Oncol. 2020 Apr;15(4):649-654. doi: 10.1016/j.jtho.2019.11.030. Epub 2019 Dec 18.
9
Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study.
Lung Cancer. 2005 Nov;50(2):227-34. doi: 10.1016/j.lungcan.2005.05.021. Epub 2005 Aug 2.

引用本文的文献

1
Effect of examining lymph nodes count on mortality risk in resected T1 non-small-cell lung cancer.
Interdiscip Cardiovasc Thorac Surg. 2024 Feb 2;38(2). doi: 10.1093/icvts/ivad195.
2
Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer.
Biomed J. 2021 Dec;44(6 Suppl 2):S190-S200. doi: 10.1016/j.bj.2020.09.006. Epub 2020 Sep 30.
4
Validation of the 2018 FIGO Staging System of Cervical Cancer for Stage III Patients with a Cohort from China.
Cancer Manag Res. 2020 Feb 25;12:1405-1410. doi: 10.2147/CMAR.S239624. eCollection 2020.
6
Intratumoral Cancer Cell Intravasation Can Occur Independent of Invasion into the Adjacent Stroma.
Cell Rep. 2017 Apr 18;19(3):601-616. doi: 10.1016/j.celrep.2017.03.064.
8
The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma.
World J Surg Oncol. 2016 Feb 16;14(1):37. doi: 10.1186/s12957-016-0791-y.
9
URGCP promotes non-small cell lung cancer invasiveness by activating the NF-κB-MMP-9 pathway.
Oncotarget. 2015 Nov 3;6(34):36489-504. doi: 10.18632/oncotarget.5351.

本文引用的文献

1
Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers.
Eur J Cardiothorac Surg. 2009 Dec;36(6):1031-6. doi: 10.1016/j.ejcts.2009.06.025. Epub 2009 Aug 18.
2
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution.
J Thorac Cardiovasc Surg. 2009 May;137(5):1180-4. doi: 10.1016/j.jtcvs.2008.09.030. Epub 2009 Mar 9.
3
The revised TNM staging system for lung cancer.
Ann Thorac Cardiovasc Surg. 2009 Feb;15(1):4-9.
4
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Mayo Clin Proc. 2008 May;83(5):584-94. doi: 10.4065/83.5.584.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验